BetterLife Pharma Inc. (BETRF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 207.85 Thousand CAD | 21.44% |
| 2023 | 1.17 Million CAD | -3.54% |
| 2022 | 1.22 Million CAD | 253.98% |
| 2021 | 345.27 Thousand CAD | -82.91% |
| 2020 | 2.02 Million CAD | -40.97% |
| 2019 | 3.42 Million CAD | 1930.07% |
| 2018 | 168.6 Thousand CAD | -20.87% |
| 2017 | 213.06 Thousand CAD | 312.78% |
| 2016 | -100.13 Thousand CAD | -9284.63% |
| 2015 | -1067.00 CAD | -100.31% |
| 2014 | 341.11 Thousand CAD | 55.76% |
| 2013 | 218.99 Thousand CAD | 124.03% |
| 2012 | 97.75 Thousand CAD | 2352.89% |
| 2011 | -4339.00 CAD | 68.96% |
| 2010 | -13.97 Thousand CAD | 52.97% |
| 2009 | -29.72 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 537.77 Thousand CAD | -51.61% |
| 2024 FY | 207.85 Thousand CAD | -82.37% |
| 2024 Q4 | 207.85 Thousand CAD | -61.35% |
| 2024 Q1 | 846.43 Thousand CAD | -28.2% |
| 2024 Q2 | 1.11 Million CAD | 31.31% |
| 2023 Q1 | 1.42 Million CAD | 16.42% |
| 2023 FY | 1.17 Million CAD | -3.54% |
| 2023 Q4 | 1.17 Million USD | -4.33% |
| 2023 Q3 | 1.23 Million CAD | -23.54% |
| 2023 Q2 | 1.61 Million CAD | 13.25% |
| 2022 Q3 | -1.75 Million CAD | 52.88% |
| 2022 FY | 1.22 Million CAD | 253.98% |
| 2022 Q4 | 1.22 Million CAD | 169.69% |
| 2022 Q2 | -3.72 Million CAD | -879.07% |
| 2022 Q1 | 477.78 Thousand CAD | 38.38% |
| 2021 Q4 | 345.27 Thousand CAD | -90.29% |
| 2021 Q2 | 2.02 Million CAD | -5.66% |
| 2021 FY | 345.27 Thousand CAD | -82.91% |
| 2021 Q1 | 2.14 Million CAD | 6.07% |
| 2021 Q3 | 3.55 Million CAD | 75.88% |
| 2020 Q3 | -4.84 Million CAD | 23.58% |
| 2020 FY | 2.02 Million CAD | -40.97% |
| 2020 Q1 | 3.99 Million CAD | 16.79% |
| 2020 Q2 | -6.33 Million CAD | -258.59% |
| 2020 Q4 | 2.02 Million CAD | 141.7% |
| 2019 Q4 | 3.42 Million CAD | 12.68% |
| 2019 Q3 | 3.03 Million CAD | -37.04% |
| 2019 Q2 | 4.82 Million CAD | 43.33% |
| 2019 FY | 3.42 Million CAD | 1930.07% |
| 2019 Q1 | 3.36 Million CAD | 1896.55% |
| 2018 Q4 | 168.6 Thousand CAD | 372.73% |
| 2018 Q3 | -61.82 Thousand CAD | -112.91% |
| 2018 Q2 | 478.72 Thousand CAD | 9.88% |
| 2018 Q1 | 435.68 Thousand CAD | 104.48% |
| 2018 FY | 168.6 Thousand CAD | -20.87% |
| 2017 Q4 | 213.06 Thousand CAD | 348.21% |
| 2017 Q2 | -3983.91 CAD | 89.22% |
| 2017 FY | 213.06 Thousand CAD | 312.78% |
| 2017 Q1 | -36.95 Thousand CAD | 63.1% |
| 2017 Q3 | -85.84 Thousand CAD | -2054.72% |
| 2016 Q3 | -187.88 Thousand CAD | 30.49% |
| 2016 FY | -100.13 Thousand CAD | -9284.63% |
| 2016 Q2 | -270.28 Thousand CAD | -700.03% |
| 2016 Q1 | -33.78 Thousand CAD | -3066.26% |
| 2016 Q4 | -100.13 Thousand CAD | 46.7% |
| 2015 Q4 | -1067.00 CAD | -100.27% |
| 2015 FY | -1067.00 CAD | -100.31% |
| 2015 Q3 | 391.56 Thousand CAD | 9.17% |
| 2015 Q2 | 358.66 Thousand CAD | 1.08% |
| 2015 Q1 | 354.84 Thousand CAD | 4.03% |
| 2014 Q3 | 233.81 Thousand CAD | 3.58% |
| 2014 Q2 | 225.74 Thousand CAD | 9.39% |
| 2014 Q1 | 206.35 Thousand CAD | -5.77% |
| 2014 FY | 341.11 Thousand CAD | 55.76% |
| 2014 Q4 | 341.11 Thousand CAD | 45.89% |
| 2013 Q4 | 218.99 Thousand CAD | 662.9% |
| 2013 Q1 | 136.01 Thousand CAD | 39.15% |
| 2013 Q2 | 160.51 Thousand CAD | 18.01% |
| 2013 FY | 218.99 Thousand CAD | 124.03% |
| 2013 Q3 | 28.7 Thousand CAD | -82.12% |
| 2012 Q1 | 134.33 Thousand CAD | 3196.04% |
| 2012 Q2 | 113.22 Thousand CAD | -15.72% |
| 2012 Q3 | 86.08 Thousand CAD | -23.97% |
| 2012 Q4 | 97.75 Thousand CAD | 13.56% |
| 2012 FY | 97.75 Thousand CAD | 2352.89% |
| 2011 FY | -4339.00 CAD | 68.96% |
| 2011 Q1 | -1198.00 CAD | 93.69% |
| 2011 Q2 | -2744.00 CAD | -129.05% |
| 2011 Q3 | -1900.00 CAD | 30.76% |
| 2011 Q4 | -4339.00 CAD | -128.37% |
| 2010 FY | -13.97 Thousand CAD | 52.97% |
| 2010 Q4 | -18.97 Thousand CAD | 0.0% |
| 2009 FY | -29.72 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 98.681% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 94.953% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.574% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.514% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 103.297% |
| Mesoblast Limited | 55.85 Million USD | 99.628% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 77.583% |
| Genus plc | 190.6 Million USD | 99.891% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 90.704% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 82.877% |
| Marizyme, Inc. | 18.56 Million USD | 98.881% |
| ContraFect Corporation | -6.02 Million USD | 103.449% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 69.434% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -54.376% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 82.011% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 90.73% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 96.222% |
| MultiCell Technologies, Inc. | 90.04 USD | -230741.848% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 128.318% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 98.394% |
| EV Biologics, Inc. | 1.36 Million USD | 84.806% |
| Q BioMed Inc. | 4.06 Million USD | 94.881% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.32% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 66.603% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 79.374% |
| Biomind Labs Inc. | 711.4 Thousand USD | 70.783% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 99.811% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 98.377% |
| Skye Bioscience, Inc. | -5.72 Million USD | 103.633% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 75.838% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -48.672% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 96.32% |
| IMV Inc. | 7.67 Million USD | 97.29% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -946.207% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 90.561% |
| GB Sciences, Inc. | 1.74 Million USD | 88.105% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 213.092% |
| HST Global, Inc. | 96.79 Thousand USD | -114.737% |
| CSL Limited | 10.52 Billion USD | 99.998% |
| Halberd Corporation | 144.72 Thousand USD | -43.621% |
| Enzolytics Inc. | 981.65 Thousand USD | 78.827% |
| Resverlogix Corp. | 6.45 Million USD | 96.778% |
| Affymax, Inc. | -5.59 Million USD | 103.714% |
| SYBLEU INC | 473.71 Thousand USD | 56.123% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 130.88% |
| argenx SE | -2.02 Billion USD | 100.01% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.521% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.442% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 92.326% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 102.351% |
| AVAX Technologies, Inc. | -5.9 Million USD | 103.521% |
| Zenith Capital Corp. | 10.06 Thousand USD | -1965.282% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.02% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -3.701% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 91.289% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -26.346% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.657% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 89.604% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 108.087% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 42.217% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 98.975% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 1234.676% |
| BioStem Technologies, Inc. | 4.47 Million USD | 95.352% |
| ONE Bio Corp. | 9.04 Million USD | 97.701% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -3.277% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 15966.412% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -0.792% |
| Agentix Corp. | 37.63 Thousand USD | -452.337% |
| LadRx Corporation | -2.03 Million USD | 110.206% |
| Cell Source, Inc. | 9.23 Million USD | 97.749% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 1118.473% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 67.276% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 67.276% |
| NovAccess Global Inc. | 2.17 Million USD | 90.459% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 97.061% |
| Itoco Inc. | 228.3 Thousand USD | 8.96% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -52.843% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 95.807% |
| Kadimastem Ltd | -253.1 Thousand USD | 182.121% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 48.277% |
| CytoDyn Inc. | 20.26 Million USD | 98.974% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 32225.193% |
| Mobile Lads Corp. | 484.23 Thousand USD | 57.076% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 2342.581% |
| Qrons Inc. | 351.42 Thousand USD | 40.855% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 97.303% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 183.267% |
| Rebus Holdings, Inc. | 305 Thousand USD | 31.852% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 95.337% |
| International Stem Cell Corporation | 2.59 Million USD | 91.975% |
| Bioxytran, Inc. | 1.89 Million USD | 89.054% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -233.024% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 90.47% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 93.947% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 97.57% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 73.098% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 116.628% |
| Neutra Corp. | 52.18 Thousand USD | -298.279% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 108.351% |
| PureTech Health plc | -167.19 Million USD | 100.124% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 184.869% |
| IXICO plc | -4.44 Million USD | 104.676% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 98.428% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.621% |
| CSL Limited | 10.52 Billion USD | 99.998% |
| Cellectis S.A. | -43.81 Million USD | 100.474% |